Erstellt von fchar99
Arrowhead Pharmaceuticals Inc. diskutieren
Arrowhead Pharmaceuticals Inc.
WKN: A2AGYB / Symbol: ARWR / Name: Arrowhead Pharma / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
59,20 €
0,14 %
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its price target lowered by analysts at Piper Sandler from $62.00 to $45.00. They now have an "overweight" rating on the stock.
Ratings data for ARWR provided by MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) was upgraded by analysts at StockNews.com to a "sell" rating.
Ratings data for ARWR provided by MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its price target raised by analysts at HC Wainwright from $60.00 to $80.00. They now have a "buy" rating on the stock.
Ratings data for ARWR provided by MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $60.00 price target on the stock.
Ratings data for ARWR provided by MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Ratings data for ARWR provided by MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Ratings data for ARWR provided by MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $60.00 price target on the stock.
Ratings data for ARWR provided by MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $42.00 price target on the stock.
Ratings data for ARWR provided by MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Ratings data for ARWR provided by MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $38.00 price target on the stock, down previously from $51.00.
Ratings data for ARWR provided by MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $60.00 price target on the stock.
Ratings data for ARWR provided by MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Ratings data for ARWR provided by MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its price target lowered by analysts at Royal Bank Of Canada from $40.00 to $38.00. They now have an "outperform" rating on the stock.
Ratings data for ARWR provided by MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Ratings data for ARWR provided by MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Ratings data for ARWR provided by MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $60.00 price target on the stock.
Ratings data for ARWR provided by MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at Piper Sandler from $45.00 to $70.00. They now have an "overweight" rating on the stock.
Ratings data for ARWR provided by MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at Royal Bank Of Canada from $45.00 to $52.00. They now have an "outperform" rating on the stock.
Ratings data for ARWR provided by MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $60.00 price target on the stock.
Ratings data for ARWR provided by MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at Bank of America Corporation from $42.00 to $62.00. They now have a "buy" rating on the stock.
Ratings data for ARWR provided by MarketBeat
Neueste Beiträge
Guggenheim in Ross Stores Inc. diskutieren